Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilazodone Sexual Functioning in Healthy Adults
NCT02097147Phase 1Completed
- Sponsor
- Forest Laboratories
- Start
- Mar 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vilazodone in major depressive disorder (MDD) (4 arms), sponsored by Forest Laboratories. Primary endpoint: Change in Changes in Sexual Functioning Questionnaire (CSFQ) total score at Day 35. Started Mar 2014; status: completed.
02
Drugs
vilazodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02097147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097147.